*As of January 3rd, 2023, GTC has expanded its RNA testing, which will now analyze 1501 genes. This includes the analysis of the previous 1408 genes with an additional 93 genes.
GTC-Hematology Profile Plus combines expression and fusion with mutation analysis in DNA and RNA. The test covers 179 DNA genes and 1501 RNA genes. This is a comprehensive evaluation of all hematologic neoplasms. However, it is especially recommended for:
-Acute Lymphoblastic Leukemia (ALL): This comprehensive assay is designed to confirm the diagnosis of Ph-ALL and Ph-like ALL and distinguish them from other types of ALL. It can be used for diagnosis as well as for monitoring. Ph-like ALL is detected in 20% to 25% of adult ALL and in 15% of pediatric ALL. Diagnosis of Ph+-ALL and Ph-like ALL is very important because TKI therapy can be helpful in most of these patients. This assay can determine most of the mutations, translocations, and expression of genes (CRLF2) associated with Ph+ ALL and Ph-like ALL.
-Diffuse Large B-cell Lymphoma (DLBCL) and other Types of Lymphoma: This assay can provide very valuable information for the management and monitoring of patients with DLBCL. It can distinguish between ABC and GCB and can help in the diagnosis of double hit lymphoma. The assay is also useful for follicular lymphoma and T-cell neoplasms.
-Acute Myeloid Leukemia (AML): Translocations in AML are very important for diagnosis, prognosis and selecting therapy. This comprehensive testing can provide a complete evaluation of fusion mRNA and mutations. It also helps in determining a diagnosis in acute leukemia with ambiguous phenotype.
Clonal Hematopoiesis of Indeterminate Potential (CHIP): Distinguish CHIP from clinically active and relevant hematologic neoplasm based on an internally developed algorithm using variant allele frequency, chromosomal structural abnormalities, clinical and laboratory data and longitudinal data. This distinction is particularly important when evaluating minimal residual disease and in the presence of other neoplastic process.
IgVH Mutation Status: IgVH mutation status is very important for prognosis and selecting therapy in patients with chronic lymphocytic leukemia (CLL).
VEXAS Syndrome: Recently described VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is caused by mutations in the UBA1 gene. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia or multiple myeloma, but characterized by fevers, low white cell count, vacuoles in bone marrow cells, dysplastic bone marrow, pulmonary inflammation, chondritis, and vasculitis. Detecting the presence of mutations in the UBA1 gene is the only way for confirming the diagnosis of this syndrome.
Epstein Barre Virus (EBV): Important for diagnosis and classification of lymphoproliferative neoplasms
Turn Around Time: 7-10 Days
- Bone marrow: 2 mL. EDTA tube is preferred.
- Peripheral blood: 5-10 mL. EDTA tube is preferred.
- Fresh Tissue
- FFPE: 1 H&E slide and 8-10 unstained slides, 5-7 microns of BM clot or tissue fixed with 10% NBF fixative. Alternatively, the FFPE block of the BM clot can be sent for sectioning in our Lab.
Specimen Preparation and Shipping Guidelines
Use the Hematology Transport Kit or Solid Tumor Transport Kit (depending on the sample type)
- Complete Requisition, making sure all sections are completed in their entirety including client information, patient Information, specimen Information and test Selection. Missing information may delay reporting of test results.
- Diagnosis/patient history is extremely important in rendering the correct interpretation of results and should also be filled out as completely as possible. A copy of a Path report should be included.
- Ensure the specimen is labeled with patient name and number. A minimum of two patient identifiers is required for each specimen
For FFPE samples:
- If sending FFPE Block-Insert up to 6 blocks into plastic block tray provided. Insert block tray into foam insert in the transport box.
- If sending slides-Insert slides into plastic slide holders provided. Insert the slide holders into the foam insert in the transport box. The container will hold up to 6 maximum slide holders.
- Place folded test requisition(s) and/or manifest(s) if ordered electronically into the transport kit.
- Close box and tuck tabs into place. No tape necessary.
For blood samples:
- Ship using a cold pack. The cold pack should not directly contact the blood tube. Ship as soon as sample collected with overnight delivery.
Genes validated and tested for Mutations in DNA testing for hematology
Request Kits
Fill out the form below to request kits. Please refer to the Specimen Requirements page for more details. *GTC will need to set you up in our system if this is your first order.
GTC uses AI in every step of our analysis and it makes a difference in helping make a new discovery daily that improve patient care.
Once the data is offloaded from the sequencer, our AI:
- Assists with mutation analysis, identifying non-mutations and artifacts
- Compares various data sets to explore disease biology
- Provides support for clinical decision making and classification of the disease
- It helps with matching patients to therapeutics and presents clinical trial options
- Aggregates data for report generation and simplifies the results so they are easily understood
Case Study: VEXAS Syndrome
Background
VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia or multiple myeloma, but characterized by fevers, low white cell count, vacuoles in bone marrow cells, dysplastic bone marrow, pulmonary inflammation, chondritis, and vasculitis. Detecting UAB1 gene mutations in the is the only way for confirming the diagnosis of this disease.Clinical History
68-year-old male With low-grade myelodysplastic syndrome and inflammatory manifestations including arthritis, chondritis or other autoimmune disorders Molecular Profiling Findings Mutations in UBA1, DNMT3A, and TET2 genesDiscussion
The presence of DNMT3A, and TET2 suggest early low-grade myelodysplastic syndrome (MDS). And the detection of UBA1 mutation along with the patient’s symptoms confirmed the diagnosis of VEXAS. This patient was undiagnosed for long period of time and became transfusion dependent. By using any of our hematology DNA, DNA+RNA or cfDNA NGS panels; we are able to accurately diagnose VEXAS syndrome. This patient and most of the patients who are currently diagnosed with VEXAS have had numerous tests and tried multiple treatments. VEXAS should be considered in patients with systemic autoinflammatory disorders as well as patients with clinical presentation of myelodysplastic syndrome.
Download PDF (VEXAS case study brochure)
References
1. David B. Beck, M.D., et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease N Engl J Med 2020; 383:2628-2638, DOI: 10.1056/NEJMoa2026834 2. James A. Poulter, et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood (2021) 137 (26): 3676–3681. 3. Marcela A. Ferrada, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS, Arithritis & Rheumatology, doi.org/10.1002/art.41743.How to complete the Genomic Testing Cooperative requisition form.
Download our
Test Requisition
Keep in mind that we do not accept blood samples directly from individuals. Talk with your M.D. to fill out the form for you.
Do You Want to Download the Sample Report?
